EVO administration in mice injected with HSC4 cells exhibited suppression of tumor growth, invasion and proliferation indicating that the anti-tumor effects of EVO may be mediated through inhibition of the HMGB1/RAGE signaling pathway [31]. Here, HMGB1 is linked to neoplasm.